4D Molecular Therapeutics FDMT Cash Flow Statement (2019-2026)

NASDAQ FDMT
$14.99 +0.29 (+1.96%)
As of: Sep 4, 2026 · 3:57 PM EDT
Reported Financials

4D Molecular Therapeutics Quarterly Cash Flow Statement

Periods 27 quarters
Latest Jun 2026

4D Molecular Therapeutics reported cash from operations of -$70.00M and free cash flow of -$69.98M for the quarter ended Jun 2026, down 61.4% year over year. This cash flow statement covers 27 quarters of results from Dec 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-22.23M-25.08M-27.39M-28.83M-25.70M-27.38M-29.18M-31.52M-10.10M-32.27M-38.26M-42.64M-43.84M-49.65M-53.52M-54.60M-56.85M19.42M-74.53M-72.77M
Share-based CompensationStock Comp.
4.08M3.73M4.83M5.02M6.04M4.35M6.59M6.42M6.02M5.91M8.23M8.19M8.83M7.58M10.66M10.45M9.68M5.55M11.54M11.74M
Cash from OperationsCash from Ops.
-15.72M-21.84M-23.55M-19.90M-21.02M-22.21M-27.91M-22.07M-1.17M-24.65M-29.09M-30.24M-29.39M-45.86M-47.76M-43.38M-46.50M28.55M-68.12M-70.00M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.38M0.38M-0.58M-0.47M-0.24M2.77M0.40M0.34M0.40M0.41M0.76M2.33M2.24M1.85M1.27M1.17M1.15M1.15M1.13M0.99M
Depreciation & Amortization (CF)Dep. & Amort.
0.38M0.39M0.41M0.47M0.52M1.01M1.03M1.08M0.99M1.10M1.17M1.19M1.19M1.10M1.05M1.17M1.26M1.22M1.27M1.28M
Change in Working Capital
Change in ReceivablesChange Receivables
-0.43M-0.74M-0.05M
Change in Account PayablesChange Payables
0.80M1.66M-1.68M0.23M-1.70M1.51M-0.33M0.95M1.37M-1.09M0.70M-0.79M-0.51M1.46M-0.23M4.55M-1.84M4.30M3.53M-4.06M
Change in Accured ExpensesChange Accured Exp.
1.06M0.54M-1.07M0.65M1.08M1.82M-3.40M1.16M3.61M2.00M-2.39M3.17M8.11M-2.37M-2.31M3.11M4.98M2.37M-4.12M6.54M
Other Working Capital ChangesOther WC Changes
-0.62M0.35M-1.22M-0.16M-0.50M-1.25M-0.30M-0.24M-0.20M0.02M0.08M-0.01M-0.00M-0.01M-0.01M-0.09M-0.09M1.38M0.83M
Investing Activities
Capital ExpendituresCapex
2.63M5.10M6.41M2.07M1.96M1.09M1.01M0.81M0.41M0.55M0.71M0.93M1.20M0.95M2.78M2.35M-0.01M-0.19M0.67M-0.02M
Change in Acquisitions & DivestmentsChange Acquisitions
5.00M12.00M65.72M205.28M-135.19M58.87M55.52M30.39M28.51M14.78M23.57M64.87M65.79M166.66M101.62M32.93M49.18M102.40M87.65M
Cash from Investing ActivitiesCash from Investing
-139.01M-32.29M-54.11M57.47M15.37M-35.78M43.13M49.29M29.98M-6.68M-263.26M-73.54M27.30M7.06M31.95M-13.85M17.78M-128.85M68.89M25.54M
Financing Activities
Other financing activitiesOther financing
0.43M0.88M1.42M-0.76M3.11M
Cash from Financing ActivitiesCash from Financing
1.98M116.14M0.63M-0.05M0.46M2.05M10.99M130.52M10.56M4.76M318.83M17.25M0.57M0.60M0.86M0.12M111.98M11.48M42.34M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
1.57M1.17M2.71M1.06M3.82M0.29M1.82M1.42M2.40M2.66M
Net Equity Issued and RepurchasedNet Equity Issued
114.30M9.65M120.07M-0.51M315.72M281.25M0.00M9.81M21.84M
Additional items
Change in Cash
-152.75M62.01M-77.03M37.51M-5.19M-55.95M26.22M157.74M39.37M-26.57M26.49M-86.53M-1.52M-38.20M-15.81M-56.37M-28.60M11.69M12.25M-2.12M
Free Cash FlowFCF
-18.36M-26.93M-29.96M-21.97M-22.98M-23.31M-28.92M-22.87M-1.58M-25.20M-29.80M-31.17M-30.59M-46.81M-50.54M-45.72M-46.49M28.74M-68.80M-69.98M
Net Cash FlowNCF
-152.75M62.01M-77.03M37.51M-5.19M-55.95M26.22M157.74M39.37M-26.57M26.49M-86.53M-1.52M-38.20M-15.81M-56.37M-28.60M11.69M12.25M-2.12M